Evidence map›Paper›PMID 39751910›Full record

ArticleCancer immunology, immunotherapy : CII2025

Unsupervised clustering reveals noncanonical myeloid cell subsets in the brain tumor microenvironment.

Ismaïl Hermelo, Tuomo Virtanen, Iida Salonen, Reetta Nätkin, Sofia Keitaanniemi, Aliisa M Tiihonen, Suvi Lehtipuro, Laura Kummola, Ella Raulamo, Kristiina Nordfors and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ismaïl HermeloProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland. ismail.hermelo@gmail.com.
Tuomo VirtanenProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Iida SalonenProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Reetta NätkinProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Sofia KeitaanniemiProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Aliisa M TiihonenProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Suvi LehtipuroProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Laura KummolaFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Ella RaulamoProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Kristiina NordforsUnit of Pediatric Haematology and Oncology, Tampere University Hospital, Tampere, Finland.
Hannu HaapasaloFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Minna RauhalaTays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland.
Juha KesseliProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Matti NykterProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Joonas HaapasaloTays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland.
Kirsi RautajokiProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland. kirsi.rautajoki@tuni.fi.

Funding

Research Council of Finland #312043Research Council of Finland #333545
6 · The paper itself

Abstract

The tumor immune microenvironment (TiME) of human central nervous system (CNS) tumors remains to be comprehensively deciphered. Here, we employed flow cytometry and RNA sequencing analysis for a deep data-driven dissection of a diverse TiME and to uncover noncanonical immune cell types in human CNS tumors by using seven tumors from five patients. Myeloid subsets comprised classical microglia, monocyte-derived macrophages, neutrophils, and two noncanonical myeloid subsets: CD3

Indexed as

Brain NeoplasmsMyeloid CellsTumor MicroenvironmentCluster AnalysisFemaleHumansMaleBrain metastasisCD19+ myeloidsCD3+ myeloidsDeconvolutionGlioblastomaImmunophenotypingSingle-cell sequencingTumor microenvironmentUnsupervised clustering

Identifiers

PMID39751910
PMCPMC11699035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.